Autoimmune Encephalitis diagnostic study of choice
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
|
Autoimmune Encephalitis Microchapters |
|
Differentiating Autoimmune Encephalitis from Other Conditions |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune Encephalitis On the Web |
Overview
Autoimmune encephalitis has no single universal diagnostic test or gold standard. Diagnosis combines clinical findings, cerebrospinal fluid (CSF) studies, neural antibodies, magnetic resonance imaging (MRI), electroencephalography (EEG), and exclusion of mimics.[1]
Diagnostic Study of Choice
Core investigations
Autoimmune encephalitis evaluation includes lumbar puncture with CSF studies and paired serum/CSF neural antibody testing, alongside MRI and EEG. Each investigation answers a different diagnostic question; none should be interpreted in isolation.[2]
| Investigation | Diagnostic contribution | Important limitation |
|---|---|---|
| Lumbar puncture and CSF analysis | Cell count, protein, glucose, CSF-restricted oligoclonal bands, immunoglobulin G (IgG) index, and infection testing assess inflammation and mimics. | Normal routine CSF does not exclude autoimmune encephalitis.[2] |
| Paired serum and CSF neural antibody testing | Identifies clinically relevant antibody-associated subtypes using validated assays. | Sensitivity and predictive value depend on antibody, specimen, assay, and clinical context.[3] |
| Brain MRI | Preferred structural imaging; medial temporal abnormalities on T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences can support limbic encephalitis. | MRI may be normal, and abnormalities can have infectious, neoplastic, or seizure-related explanations.[4] |
| EEG | Detects slowing, epileptiform activity, and non-convulsive seizures or status epilepticus. | Findings usually support neurological dysfunction rather than establish an autoimmune cause.[4] |
| Brain fluorodeoxyglucose positron emission tomography (FDG-PET) | Selected adjunct when clinical suspicion remains high and conventional investigations are inconclusive. | Metabolic abnormalities are nonspecific; this is not a stand-alone confirmatory test.[4] |
| Brain biopsy | Reserved for selected atypical cases or suspected alternative diagnoses, such as neoplasm. | Not routinely required; inflammatory infiltrates alone do not establish autoimmune causation.[4] |
Antibody testing and confirmation
Autoimmune encephalitis antibody testing should generally examine both serum and CSF. CSF is more informative for N-methyl-D-aspartate receptor (NMDAR) and glial fibrillary acidic protein (GFAP) antibodies, whereas serum can be more sensitive for leucine-rich glioma-inactivated protein 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) antibodies.[1]
- NMDAR antibody encephalitis: CSF IgG antibodies against NMDAR subunit 1 (GluN1), detected with validated methods in a compatible clinical syndrome after reasonable exclusion of alternatives, provide disease-specific confirmation.[5]
- Diagnostic performance example: In a study of 250 patients with established anti-NMDAR encephalitis, antibodies were detected in CSF in 250/250 (100%) and in serum in 214/250 (85.6%) using the study's combined methods. These are study-specific findings, not universal sensitivity estimates for every assay or autoimmune encephalitis subtype.[6]
- Assay confirmation: Unexpected results require clinical reassessment and, where appropriate, confirmation using another assay or a specialist reference laboratory. A 2024 nationwide study demonstrated that positive predictive value can remain modest despite high analytical specificity.[3]
- Serum-only results: Interpretation must account for the specific antibody. In particular, negative CSF testing does not exclude compatible LGI1 antibody encephalitis; a low-titer serum result should not automatically be dismissed or accepted without clinical correlation.[7]
Sequence of diagnostic studies
Autoimmune encephalitis investigations should proceed in parallel when clinically appropriate:
- Establish the syndrome and consider mimics: Assess symptom onset, progression, neurological findings, medication or toxic exposures, metabolic disturbance, infection, and neoplasm.[4]
- Obtain MRI, EEG, and CSF studies promptly: Perform lumbar puncture when safe; investigate infectious encephalitis, particularly herpes simplex virus (HSV) encephalitis, according to the presentation. An early negative HSV polymerase chain reaction (PCR) test may require repeat testing if suspicion persists.[2]
- Send paired serum/CSF antibody studies: Use clinically validated testing appropriate to the phenotype; collect samples before immunotherapy when feasible.[1]
- Interpret the complete evidence: Review antibody identity, specimen, assay, imaging, EEG, and CSF findings together. Persistent uncertainty or discordant findings warrants specialist review and targeted additional testing.[7]
Awaiting antibody results should not delay specialist consideration of empiric immunotherapy when clinical suspicion is high and major alternative diagnoses have been reasonably excluded.[4]
Diagnostic Criteria
Autoimmune encephalitis diagnostic certainty is classified using published consensus criteria. The following summaries condense selected criteria from the 2016 Graus framework, which remains incorporated into subsequent guidance.
| Category | Required findings |
|---|---|
| Possible autoimmune encephalitis | All 3:
|
| Definite autoimmune limbic encephalitis (antibody-independent criteria) | The classic framework requires all 4:
|
| Probable antibody-negative autoimmune encephalitis | All 4:
|
Antibody-positive cases may be diagnosed without fulfilling all four antibody-independent limbic criteria.[1]
- Possible is not definite: Possible autoimmune encephalitis criteria are an entry point to further evaluation. A validation study found substantially lower specificity for this category than for more restrictive probable or definite categories.[8]
- Negative antibody testing is not sufficient for seronegative diagnosis: Probable antibody-negative autoimmune encephalitis requires the additional clinical and objective findings above. EEG abnormalities alone do not satisfy the required inflammatory evidence categories.[8]
- Nonspecific antibodies are not confirmation: Thyroid peroxidase antibodies and non-antigen-specific voltage-gated potassium channel (VGKC)-complex results should not be used as confirmatory tests for autoimmune encephalitis.[2]
Children and adolescents
Autoimmune encephalitis diagnosis in children requires age-appropriate assessment of developmental regression, cognition, behavior, movement, and seizures. The pediatric international working-group provisional framework adapts adult criteria and emphasizes supportive investigations and exclusion of mimics; diagnosis is not dependent on antibody positivity alone.[9]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Hahn C, Budhram A, Alikhani K; et al. (2024). "Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults". Canadian Journal of Neurological Sciences. 51 (6): 734–754. doi:10.1017/cjn.2024.16. PMID 38312020 Check
|pmid=value (help). - ↑ 2.0 2.1 2.2 2.3 Michael BD, Huang Y, McKeever S; et al. (2026). "Management of suspected infectious and autoimmune encephalitis in adults – National Guidelines from the United Kingdom Joint Societies". Journal of Infection: 106873. doi:10.1016/j.jinf.2026.106873. PMID 42863638 Check
|pmid=value (help). - ↑ 3.0 3.1 Kerstens J, Schreurs MWJ, de Vries JM; et al. (2024). "Autoimmune Encephalitis and Paraneoplastic Neurologic Syndromes: A Nationwide Study on Epidemiology and Antibody Testing Performance". Neurology: Neuroimmunology & Neuroinflammation. 11 (6): e200318. doi:10.1212/NXI.0000000000200318. PMID 39467237 Check
|pmid=value (help). - ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Abboud H, Probasco JC, Irani S; et al. (2021). "Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management". Journal of Neurology, Neurosurgery & Psychiatry. 92 (7): 757–768. doi:10.1136/jnnp-2020-325300. PMID 33649022 Check
|pmid=value (help). - ↑ 5.0 5.1 5.2 Graus F, Titulaer MJ, Balu R; et al. (2016). "A clinical approach to diagnosis of autoimmune encephalitis". The Lancet Neurology. 15 (4): 391–404. doi:10.1016/S1474-4422(15)00401-9. PMID 26906964.
- ↑ Gresa-Arribas N, Titulaer MJ, Torrents A; et al. (2014). "Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study". The Lancet Neurology. 13 (2): 167–177. doi:10.1016/S1474-4422(13)70282-5. PMID 24360484.
- ↑ 7.0 7.1 Endres D, von Zedtwitz K, Tebartz van Elst L; et al. (2026). "Diagnosing autoimmune encephalitis in psychiatry: clinical recommendations and unresolved challenges from the GENERATE network". Molecular Psychiatry. doi:10.1038/s41380-026-03871-2. PMID 42786262 Check
|pmid=value (help). - ↑ 8.0 8.1 van Steenhoven RW, de Vries JM, Bruijstens AL; et al. (2023). "Mimics of Autoimmune Encephalitis: Validation of the 2016 Clinical Autoimmune Encephalitis Criteria". Neurology: Neuroimmunology & Neuroinflammation. 10 (6): e200148. doi:10.1212/NXI.0000000000200148. PMID 37582614 Check
|pmid=value (help). - ↑ Cellucci T, Van Mater H, Graus F; et al. (2020). "Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient". Neurology: Neuroimmunology & Neuroinflammation. 7 (2): e663. doi:10.1212/NXI.0000000000000663. PMID 31953309.